Company
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases.
20 stories
Zynerba Pharmaceuticals adds pharma exec to its board
Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies
Baird analysts stay Neutral on biotech sector as 2019 gets underway
Vertex Pharmaceuticals, Intercept Pharmaceuticals and Aimmune Therapeutics are three biotech stocks Baird's Brian Skorney describes as diamonds in the rough
Moderna is biggest biotech IPO, draws $604 million despite turbulent market
The Cambridge biotech, which is developing novel messenger RNA technology, priced at the midpoint of expected range in a sign of resiliency but shares declined in their first few minutes of trading
Large-cap biotech companies seem poised to outperform in 2Q, says Oppenheimer analyst
'We remain cautiously bullish on the sector, albeit with a stock-picking approach,' writes Hartaj Singh
US stocks heading north into close; ECB meet in focus
US shares are heading higher into the close on Wednesday..
IBM, Vertex Pharmaceuticals and more
We are looking at what moved the needle last night after hours in New York
Vertex Pharmaceuticals surges on cystic fibrosis drug results
In premarket dealing, Vertex shares are up US$35.85 or 27% changing hands at US$167.80.
Del Taco serves quarterly revenue growth as it expands stores
Del Taco expects further revenue growth in 2017 as it plans to open more restaurants
Concert Pharmaceuticals sells cystic fibrosis assets to Vertex Pharmaceuticals as it swings to full year loss
Concert Pharmaceuticals has swung to a full year loss after revenue plunged but shares have jumped on news that Vertex Pharmaceuticals is buying its cystic fibrosis assets
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
US stocks hit record highs as Dow adds 300 points, but pharma sink
US stocks hit fresh record highs on Wednesday, with the S&P 500 marking its biggest single-day gains since the presidential elections, as investors largely shrugged off declines in health care stocks
Analyst positive on Vertex Pharmaceuticals growth as testing moves ahead
CF therapy producer has strong sales as they test new products
Silence Therapeutics bolsters board
Silence Therapeutics has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments
Wall Street trades in narrow range as investors assess data, yields
U.S. stocks traded in a narrow range today as corporate deal activity was offset by concern a fixed-income selloff may resume, and investors considered a downbeat retail sales report. The S&P 500 (INDEXSP:.INX) inched down less than 0.1
U.S. stock-index futures pare early gains after retail sales, import-price index disappoint
U.S. stock-index futures trimmed early gains after a slate of weaker-than-expected economic data. Futures for the Dow Jones Industrial Average climbed 0.1 percent, while those for the S&P 500 index gained 0.2 percent. Danaher (NYSE:DHR)